IGC Pharma announced that the Visionary Investigators Network (VIN) will serve as a new clinical research site for its Phase 2 CALMA trial, which evaluates the cannabinoid‑based therapy IGC‑AD1 for agitation in Alzheimer’s disease.
VIN operates embedded research programs within private neurology practices, giving IGC access to well‑characterized patients while maintaining continuity of clinical care. The model is expected to accelerate enrollment and data collection, helping the trial reach its read‑out scheduled for later in 2026.
As of February 2 2026, the CALMA trial had achieved roughly 70 % of its planned enrollment, with completion projected for mid‑2026. Adding VIN is part of IGC’s strategy to sustain enrollment momentum and ensure timely data for the read‑out.
CEO Ram Mukunda said the trial “continues as designed, and our focus is execution through enrollment completion. VIN brings an experienced, practice‑integrated research model that aligns well with our Phase 2 execution priorities and supports continued enrollment momentum.” The expansion underscores IGC’s commitment to advancing IGC‑AD1 through the clinical development pipeline.
IGC‑AD1 is a partial CB1 receptor agonist with anti‑inflammatory action, formulated with low doses of THC. The CALMA trial is a randomized, double‑blind, placebo‑controlled study assessing safety and efficacy in agitation associated with Alzheimer’s disease dementia.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.